SCHEMBL15713347

SCHEMBL15713347

O=C(c1ccc(NS(=O)(=O)c2cccc(C(F)(F)F)c2)cc1)N1CC(O)(Cc2ccccc2)C1

nearest known ligand 0.83

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PKLR P30613 12/20 0.83
▸ RXFP1 Q9HBX9 1/20 0.53
▸ ALDH1A1 P00352 3/20 0.52
▸ NR3C1 P04150 1/20 0.51
▸ PGR P06401 1/20 0.51
▸ AR P10275 1/20 0.51
▸ ESR2 Q92731 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ GAA P10253 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ HPGD P15428 1/20 0.51
▸ CASP1 P29466 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ CASP7 P55210 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ MAPT P10636 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16084080 0.91 PKLR (1.00) PKLRRXFP1ALDH1A1CYP3A4GAA
SCHEMBL15713683 0.90 PKLR (0.67) PKLRRXFP1ALDH1A1ARGAA
SCHEMBL15713924 0.86 PKLR (0.84) PKLRALDH1A1GAASMN1; SMN2
SCHEMBL15713346 0.86 PKLR (0.82) PKLRPGR
SCHEMBL15713609 0.84 PKLR (0.63) PKLRALDH1A1PGR
SCHEMBL15713676 0.82 PKLR (0.84) PKLR
SCHEMBL15713345 0.81 PKLR (0.69) PKLRALDH1A1GAASMN1; SMN2
SCHEMBL15713606 0.81 PKLR (0.81) PKLRALDH1A1ARGAASMN1; SMN2
SCHEMBL16083871 0.80 PKLR (0.82) PKLRRXFP1ALDH1A1CYP3A4GAA
SCHEMBL15713928 0.80 PKLR (0.82) PKLRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458132-B2 Therapeutic compounds and compositions and their use as PKM2 modulators AGIOS PHARMACEUTICALS, INC (US) 2016-10-04 — — US disclosed
US-20150307473-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS AGIOS PHARMACEUTICALS, INC (US) 2015-10-29 — — US disclosed
WO-2014074848-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS AGIOS PHARMACEUTICALS, INC. (US) 2014-05-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307473-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS PDK1, PDK2, PDK3 PKLR 12/4885RXFP1 2694/4885ALDH1A1 1314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback